Peroxisome proliferator-actived receptor-? ligand troglitazone induces apoptosis in renal cell carcinoma
- VernacularTitle:曲格列酮诱导肾癌细胞的凋亡
- Author:
Fengguang YANG
;
Zhiwen ZHANG
;
Dianqi XIN
;
Changjin SHI
;
Xueqing WU
;
Wujiang LIU
;
Yinglu GUO
;
Jieping WU
;
- Publication Type:Journal Article
- Keywords:
PPAR;
Kidney neoplasms;
Apoptosis;
Troglitazone
- From:
Journal of Peking University(Health Sciences)
2004;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the expression of peroxisome proliferator actived receptor ? (PPAR ?)and the inducement of apoptosis by PPAR ? ligand in renal cell carcinoma(RCC) derived cell lines.Methods:RT-PCR and Western blot analysis were performed to determined the expression of PPAR ? mRNA and protein in two RCC derived cell lines(786 O and A498) and two normal kidney(NK) derived cell lines(HK 2 and HMCC). Two RCC cell lines were treated with 50 ?mol/L troglitazoned for and evaluated for the effects of antidiabetic thiazolidinediones (TZDs) on the cells apoptosis by fluorescence microscopy and DNA ladder assay.The mutative expressions of Bcl 2 and Bax before and after TZDs treatment were also performed by western blot analysis. Results: The expression of PPAR ? was observed to be stronger in 786 O and A498 cells than in HK 2 and HMCC cells by RT-PCR and Western blot analysis. Treated with 50 ?mol/L troglitazone (for 48 h) it induced typical apoatosis in 786 O and A498 cells. After treatment, a decrease in Bcl 2 expression in RCC cells was observed by Western blot analysis,and the expression of Bax,however,was up regulated.Conclusion: The results reveal that troglitazone has the tumor suppressive effect on RCC cells. High affinity PPAR ? ligands (TZDs) may be the candidates for a novel approach to the treatment of this refractory neoplasm.
